[144] Vertex Pharmaceuticals Inc SEC Filing

Rhea-AI Filing Summary

Vertex Pharmaceuticals (VRTX) Form 144 notice: An individual filer intends to sell 266 shares of Vertex common stock through Fidelity Brokerage Services on the NASDAQ, with an aggregate market value of $102,859.54 and approximately 256,390,651 shares outstanding. The securities were acquired on May 1, 2024 via restricted stock vesting from the issuer and were paid as compensation on the same date. The approximate sale date is listed as August 27, 2025. The filer reports no other sales in the past three months and affirms no undisclosed material adverse information.

Insights

Securities Analyst

TL;DR: Small insider sale in absolute terms; unlikely to be material to VRTX but noteworthy as a scheduled Rule 144 disposition.

The filing documents a planned off-exchange sale under Rule 144 of 266 vested restricted shares, valued at about $102.9k, executed through Fidelity and scheduled for August 27, 2025. Given the issuer's outstanding share count (~256.4 million), this represents an immaterial dilution percentage and is routine for insiders disposing of vested compensation. No prior sales in the past three months were reported, and the filer certifies lack of undisclosed material information. Impact on market valuation is likely negligible.

Compliance Officer

TL;DR: The Form 144 appears compliant: acquisition, nature, payment, broker, and intended sale date are disclosed.

The notice provides the required Rule 144 elements: acquisition date (05/01/2024), nature of acquisition (restricted stock vesting), consideration (compensation), broker details, number of shares, aggregate market value, and planned sale date. The filer signed the standard representation regarding material nonpublic information and reported no sales in the prior three months. From a compliance perspective, the filing meets disclosure expectations for a standard Rule 144 sale.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	266	102859.54	256390651	08/27/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	05/01/2024	Restricted Stock Vesting	Issuer			266	05/01/2024	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the VRTX Form 144 disclose about the planned sale?

The notice discloses a planned sale of 266 shares of Vertex common stock through Fidelity on NASDAQ with aggregate market value of $102,859.54, approximate sale date 08/27/2025.

How and when were the shares being sold acquired according to the filing?

The shares were acquired on 05/01/2024 through restricted stock vesting from the issuer and were paid as compensation on that date.

Does the Form 144 report any other sales by the filer in the past three months?

No. The filing states "Nothing to Report" for securities sold during the past three months.

What broker is handling the proposed sale in the Form 144?

The broker listed is Fidelity Brokerage Services LLC at the address provided (900 Salem Street, Smithfield, RI 02917).

What representation does the filer make about material information?

By signing, the filer represents they do not know any material adverse information about the issuer that has not been publicly disclosed.